Cliff Ansel
CEO
Claimed by owner Respinova
Former names:
Novel Treatment for COPD and Inhaled Therapeutics
Respinova
www.prnewswire.com
•
Apr 6, 2021
Respinova Granted FDA 510(k) Clearance for Pulsehaler™
www.israel21c.org
•
Jun 1, 2020
COPD innovation may keep Covid patients off ventilators
sciencebusiness.net
•
Nov 12, 2019
Israeli research breathes new life into EU battle against a life-threatening disorder
globenewswire.com
•
Jun 19, 2018
Respinova Wins Chiesi Spain and Richi Entrepreneurs Second Call
About
Respinova has developed the PulseHaler, a noninvasive technology that aims to treat the core pathophysiology of chronic obstructive pulmonary disorder (COPD). The PulseHalers proprietary multi-frequency air pressure pulse technology is an easy-to-use treatment intended for patients diagnosed with COPD of all severity stages.
The companys technology was successfully validated in two clinical studies. The first study demonstrated PulseHalers ability to improve the lung function, exercise capacity, and quality of life of COPD patients. The second study demonstrated the technologys ability to deliver drugs more effectively to the lung periphery.
The PulseHaler stands alongside leading COPD drugs in managing the disease and enhancing the patients functional capacity and quality of life and has the potential to become a standard of care in COPD management.
The commercialization of PulseHaler was co-funded by the European Unions Horizon 2020 program. The device was granted an FDA 510(k) clearance in April 2021.
The companys technology was successfully validated in two clinical studies. The first study demonstrated PulseHalers ability to improve the lung function, exercise capacity, and quality of life of COPD patients. The second study demonstrated the technologys ability to deliver drugs more effectively to the lung periphery.
The PulseHaler stands alongside leading COPD drugs in managing the disease and enhancing the patients functional capacity and quality of life and has the potential to become a standard of care in COPD management.
The commercialization of PulseHaler was co-funded by the European Unions Horizon 2020 program. The device was granted an FDA 510(k) clearance in April 2021.
Primary Sector
Life Sciences & HealthTech
Products
Pulsehaler
Geographic markets
-
News
(4)
www.prnewswire.com
•
Apr 6, 2021
Respinova Granted FDA 510(k) Clearance for Pulsehaler™
www.israel21c.org
•
Jun 1, 2020
COPD innovation may keep Covid patients off ventilators
sciencebusiness.net
•
Nov 12, 2019
Israeli research breathes new life into EU battle against a life-threatening disorder
globenewswire.com
•
Jun 19, 2018
Respinova Wins Chiesi Spain and Richi Entrepreneurs Second Call
The Team
(5)
YA
Yuval Avni
Founder & CTO
PNG
Prof. Noam Gavriely
CMO
AS
Ariel Shvager
VP Engineering
RA
Ran Amos
Director of Quality
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Non-Equity Funding
Grant
$60K
Dec 2017
1 Grantors
$60K
Grant
$2.7M
Feb 2019
1 Grantors
$2.7M
Media gallery
(0)Locations
Israel
8 Hahoshlim St, Herzliya, Israel
Locations
Israel
8 Hahoshlim St, Herzliya, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,